US4434157A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of recovering cell antigen and preparation of feline leukemia vaccine therefrom
Assignee: Ohio State University Research Foundation
•
Filing: 1982-04-07
•
Granted: 1984-02-28
•
Expires: 2002-04-07
Abstract
Abstract Disclosed is a vaccine which prevents disease caused by Feline leukemia virus (FeLV) and which comprises a protease enzyme-inhibited, cell-free, ostensibly virusfree, in vitro produced feline leukemia neoantigens including FOCMA which evokes an immune response in cats by the appearance of antibodies thereto and a FeLV virion gp70 neoantigen which evokes an immune response in cats by the appearance of antibodies thereto. A novel method for making the vaccine is disclosed also.
Inventors
- 👤 Richard G. Olsen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 14:58
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K39/00; C12; C12N; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13022; Y; Y10; Y10S; Y10S424/00; Y10S424/819
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
104 words
A method for recovering virus-free, cell-free Feline leukemia associated neoantigen from cells infected with Feline Leukemia virus, which comprises: (a) culturing said cells in a serum-containing growth medium; (b) transferring and maintaining said cultured cells in a serum-free medium under conditions and for a time adequate to accumulate said neoantigen shed from said cells in said serum-free medium; (c) separating said cultured cells from the associated serum-free medium, thereby producing a cell-free, serum-free medium; (d) reducing the volume of said cell-free, serum-free medium without substantial loss of said neoantigen therefrom, thereby producing a neoantigen-rich medium; and (e) inhibiting protease enzymes in said neoantigen-rich medium.
Claim 2
Independent Claim
104 words
A method for recovering virus-free, cell-free Feline leukemia associated neoantigen from cells infected with Feline Leukemia virus, which comprises: (a) culturing said cells in a serum-containing growth medium; (b) transferring and maintaining said cultured cells in a serum-free medium under conditions and for a time adequate to accumulate said neoantigen shed from said cells in said serum-free medium; (c) separating said cultured cells from the associated serum-free medium, thereby producing a cell-free, serum-free medium; (d) reducing the volume of said cell-free, serum-free medium without substantial loss of said neoantigen therefrom, thereby producing a neoantigen-rich medium; and (e) inhibiting protease enzymes in said neoantigen-rich medium.
Claim 3
Dependent Claim
13 words
The method of claim 1 wherein said cultured cells are feline lymphoblastoid cells.
Claim 4
Dependent Claim
15 words
The method of claim 1 wherein said cells are separated in step (c) by centrifugation.
Claim 5
Dependent Claim
25 words
The method of claim 1 wherein said concentration step (d) includes at least one of the following methods: lyophilization, ultrafiltration, or continuous flow molecular filtration.
Claim 6
Dependent Claim
40 words
The method of claim 1 or 3 wherein said concentration step (d) includes continuous-flow molecular filtration with a filter having an exclusion size of about 10,000 daltons to produce a neoantigen-containing retenate followed by freezing and lyophilization of said retenate.
Claim 7
Dependent Claim
23 words
The method of claim 1 wherein said inhibition of protease enzymes is effected by adding an effective proportion of a protease enzyme inhibitor.
Claim 8
Dependent Claim
26 words
The method of claim 6 wherein said protease enzyme inhibitor comprises at least one of aprotinin, antipapain, leupeptin, ovomucoid, soybean trypsin inhibitor and tolyl-L-lysine chloromethyl ketone.
Claim 9
Dependent Claim
26 words
The method of claim 1 wherein said inhibition of protease enzymes is effected by heating said neoantigen to a temperature effective to inhibit protease enzymes therein.
Claim 10
Dependent Claim
29 words
The method of claim 1 wherein said inhibition of protease enzymes is effected by changing the pH of said neoantigen to a value effective to inhibit protease enzymes therein.
Claim 11
Dependent Claim
30 words
The method of claim 1 wherein said inhibition of protease enzymes is effected by changing the ionic strength of said neoantigens to a value effective to inhibit protease enzymes therein.
Claim 12
Dependent Claim
10 words
The neoantigen concentrate produced by the method of claim 1.
Claim 13
Dependent Claim
10 words
The neoantigen concentrate produced by the method of claim 5.
Claim 14
Dependent Claim
10 words
The neoantigen concentrate produced by the method of claim 6.
References Cited (Backward Citations)
US4086134A
Cited
DE2951509A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-02-27 | 1987-08-29 | 1988-02-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-02-27 | 1991-08-29 | 1992-02-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-02-27 | 1995-08-29 | 1996-02-28 | $7700.00 | Window Closed / Lapsed |